Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience
|3||Active, not recruiting||
Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
† Study has passed its completion date and status has not been verified in more than two years.